GILZ regulates type I interferon release and sequesters STAT1. Issue 131 (July 2022)

• Record Type: Journal Article
• Authors: Nataraja, Champa; Flynn, Jacqueline; Dankers, Wendy; Northcott, Melissa; Zhu, Wendy; Sherlock, Rochelle; Bennett, Taylah J.; Russ, Brendan E.; Miceli, Iolanda; Pervin, Mehnaz; D'Cruz, Akshay; Harris, James; Morand, Eric F.; Jones, Sarah A.
• Is Part Of: Journal of autoimmunity. Issue 131(2022)
• Publication Date: 2022-07
• Subjects: Glucocorticoids -- Autoimmunity -- Interferon -- STAT1 -- Systemic lupus erythematosus -- GILZ; Autoimmunity -- Periodicals; Autoimmune diseases -- Periodicals; Autoantibodies -- Periodicals; Autoimmune Diseases -- Periodicals; Auto-immunité -- Périodiques; Maladies auto-immunes -- Périodiques; Electronic journals; 616.978005
• DOI: 10.1016/j.jaut.2022.102858
• Languages: English
• ISSNs: 0896-8411

Abstract

Abstract: Glucocorticoids remain a mainstay of modern medicine due to their ability to broadly suppress immune activation. However, they cause severe adverse effects that warrant urgent development of a safer alternative. The glucocorticoid-induced leucine zipper (GILZ) gene, TSC22D3, is one of the most highly upregulated genes in response to glucocorticoid treatment, and reduced GILZ mRNA and protein levels are associated with increased severity of inflammation in systemic lupus erythematosus (SLE), Ulcerative Colitis, Psoriasis, and other autoimmune/autoinflammatory diseases. Here, we demonstrate that low GILZ permits expression of a type I interferon (IFN) signature, which is exacerbated in response to TLR7 and TLR9 stimulation. Conversely, overexpression of GILZ prevents IFN-stimulated gene (ISG) up-regulation in response to IFNα. Moreover, GILZ directly binds STAT1 and prevents its nuclear translocation, thereby negatively regulating IFN-induced gene expression and the auto-amplification loop of the IFN response. Thus, GILZ powerfully regulates both the expression and action of type I IFN, suggesting restoration of GILZ as an attractive therapeutic strategy for reducing reliance on glucocorticoids. Highlights: The glucocorticoid-induced protein GILZ suppresses multiple inflammatory pathways in autoimmune diseases. Low GILZ is permissive of SLE development, and glucocorticoid induction of GILZ is protective in patients with SLE. GILZ negatively regulates type I IFN production in response to TLR stimulation in SLE-active pathways. GILZ sequesters pSTAT1 in the cytoplasm to directly prevent IFN-induced gene transcription.